<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952974</url>
  </required_header>
  <id_info>
    <org_study_id>8205</org_study_id>
    <nct_id>NCT04952974</nct_id>
  </id_info>
  <brief_title>B-cell Chronic Lymphoid Malignancies Markers</brief_title>
  <acronym>MALYZOMA-II</acronym>
  <official_title>Study of Cell Markers of Marginal Zone Lymphoma and Other B-cell Chronic Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very&#xD;
      variable prognosis and treatment (some of them can remain untreated). The diagnosis of these&#xD;
      malignancies relies on the study of the morphology of tumoral cells and the expression by&#xD;
      these cells of several markers, mainly via a technical approach called flow cytometry.&#xD;
      Because the markers currently used remain imperfect, additional ones are needed for an&#xD;
      accurate diagnosis that affect both prognosis and treatment.&#xD;
&#xD;
      In addition, because numerous markers are used at the diagnosis, there is a need of tools&#xD;
      that synthetize the multi-dimensional structure of the data obtained.&#xD;
&#xD;
      The primary purpose of this study is to detect new markers that can be of help for the&#xD;
      diagnosis of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies.&#xD;
&#xD;
      The secondary purpose of this study is to obtain a statistical algorithm that allow a good&#xD;
      prediction of the different sub-types of chronic B-cell malignancies mainly using the results&#xD;
      of flow cytometry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective study of laboratory data from patients with B lymphoid hemopathy, mainly lymphoma in the marginal zone</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Hairy Cell Leukemia</condition>
  <condition>Follicular Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 18 years-old with of Marginal Zone Lymphoma and other B-cell chronic lymphoid&#xD;
        malignancies&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients over 18 years-old with of Marginal Zone Lymphoma and other B-cell chronic&#xD;
             lymphoid malignancies&#xD;
&#xD;
          -  patients that gave their informed consent for the conservation of blood or bone marrow&#xD;
             cells (primary objective 1)&#xD;
&#xD;
          -  patients that gave their informed consent for the retrospective use of their clinical&#xD;
             and biological data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients under guardianship or curatorship&#xD;
&#xD;
          -  patients who did not gave their consent for the use of their cells and/or data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent MAUVIEUX, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hematology Laboratory - Strasbourg University Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent MAUVIEUX, MD, PhD</last_name>
    <phone>33 3 88 12 75 27</phone>
    <email>laurent.mauvieux@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology Laboratory - Strasbourg University Hospitals</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MAUVIEUX, MD, PhD</last_name>
      <phone>33 3 88 12 75 27</phone>
      <email>laurent.mauvieux@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent MAUVIEUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent MIGUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline MAYEUR-ROUSSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaut FABACHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravzan BIZOI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic B-cell malignancies</keyword>
  <keyword>Flow cytometry</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Statistical algorithms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

